Ribapak and Joint swelling - a phase IV clinical study of FDA data

Summary:

Joint swelling is reported as a side effect among people who take Ribapak (ribavirin), especially for people who are male, 50-59 old, have been taking the drug for < 1 month also take Pegasys, and have Hepatitis c.

The phase IV clinical study analyzes which people have Joint swelling when taking Ribapak. It is created by eHealthMe based on reports of 3,390 people who have side effects when taking Ribapak from the FDA, and is updated regularly.

What is Ribapak?

Ribapak has active ingredients of ribavirin. eHealthMe is studying from 3,392 Ribapak users. Check the latest studies of Ribapak.

What is Joint swelling?

Joint swelling is found to be associated with 2,122 drugs and 2,940 conditions by eHealthMe. Check the latest studies of Joint swelling.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

3,390 people reported to have side effects when taking Ribapak.
Among them, 18 people (0.53%) have Joint swelling.

Among these 18 people:

How long have people been on Ribapak when they have Joint swelling? *

What is the gender of people who have Joint swelling when taking Ribapak? *

female: 41.18 %
male: 58.82 %

What is the age of people who have Joint swelling when taking Ribapak? *

What are other drugs people take besides Ribapak? *

What are other side effects people have besides Joint swelling? *

Nausea (feeling of having an urge to vomit): 11 people, 61.11%
Weakness: 7 people, 38.89%
Depression: 6 people, 33.33%
Rashes (redness): 6 people, 33.33%
Fatigue (feeling of tiredness): 6 people, 33.33%
Anaemia (lack of blood): 6 people, 33.33%
Weight Decreased: 5 people, 27.78%
Diarrhea: 5 people, 27.78%
Taste - Impaired: 5 people, 27.78%
Joint Pain: 5 people, 27.78%

What are the existing conditions these people have? *

Hepatitis C: 15 people, 83.33%
Depression: 3 people, 16.67%
White Blood Cell Count Decreased: 1 person, 5.56%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.56%
Diabetes: 1 person, 5.56%
Anaemia (lack of blood): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Ribapak and have Joint swelling?

- Check whether Joint swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ribapak:

Ribapak (3,392 reports)

Joint swelling treatments and more:

Joint swelling (143,797 reports)

Browse all side effects of Ribapak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint swelling:

Joint swelling (2,122 drugs)

Browse all the conditions that are associated with Joint swelling:

Joint swelling (2,940 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Ribapak) and Ribapak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.